Association between mycophenolic acid treatment and infection with specific strains of Pneumocystis jirovecii in solid organ transplant recipients in France and Switzerland: a multicentre, retrospective, cross-sectional study
The Lancet Microbe · 2025
DOI: 10.1016/j.lanmic.2025.101146 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Lancet Microbe, 2025. Verfasst von Claire V Hoffmann und 8 weiteren Autor:innen. Beteiligte Einrichtung: CHU de Brest, Laboratoire de Parasitologie-Mycologie, Brest, France; Univ Brest, Univ Angers, Infections Respiratoires Fongiques, Brest, France. Hauptthemen laut MEDLINE: Pneumocystis carinii, Mycophenolic Acid, Pneumonia, Pneumocystis, Immunosuppressive Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chiesi Pharmaceuticals.
Abstract (Originalsprache)
BACKGROUND: Pneumocystis pneumonia (PCP) case clusters involving solid organ transplant (SOT) recipients have been reported worldwide. Mycophenolic acid, an immunosuppressant used to prevent rejection in SOT recipients that targets the inosine 5'-monophosphate dehydrogenase (IMPDH) protein, has been hypothesised to exert selective pressure on Pneumocystis jirovecii, with the missense mutation G1020A (Ala261Thr) in the impdh gene a possible marker of such selective pressure. The aim of this study was to test the hypothesis that SOT recipients harbour P jirovecii with mutations in the impdh gene and are infected with specific P jirovecii strains. METHODS: In this retrospective, multicentre, cross-sectional study of nationally representative, individual-level data, we included SOT recipients, regardless of the organ transplanted, involved or not in a PCP case cluster, and non-SOT recipients (control group) without mycophenolic acid exposure, diagnosed with PCP from 26 French and one Swiss secondary health-care centres. We included patients aged 18 years or older for whom archival P jirovecii DNA extracts were available in sufficient quantity and quality. P jirovecii specimens were characterised using a multilocus sequence typing method including impdh gene analysis. The primary outcome of this study was the detection of the G1020A (Ala261Thr) mutation in the impdh gene. A multivariable logistic regression was done to assess the relation between this mutation and the following variables retrieved from medical records: age, mycophenolic acid exposure at the time of PCP diagnosis, involvement in a PCP case cluster, PCP prophylaxis, and clinical outcome. FINDINGS: 58 SOT recipients (44 treated with mycophenolic acid) and 59 non-SOT recipients (control group; not treated with mycophenolic acid) diagnosed with PCP between Jan 1, 2001, and Dec 31, 2021, were enrolled. The G1020A (Ala261Thr) mutation was detected in P jirovecii specimens from 40 (68·9%) SOT recipients (37 treated with mycophenolic acid) and in none of the P jirovecii specimens from the patients in the control group. The multivariable analysis showed that the allele characterised by the G1020A mutation was associated with mycophenolic acid exposure at the time of PCP diagnosis (adjusted odds ratio 73·61 [95% CI 17·41-455·70]; p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- CHU de Brest, Laboratoire de Parasitologie-Mycologie, Brest, France; Univ Brest, Univ Angers, Infections Respiratoires Fongiques, Brest, France.
- CHU de Brest, Service de néphrologie et transplantations rénales, Brest, France; Université de Brest, UMR1227, Lymphocytes B et Autoimmunité, Inserm, Labex IGO, Brest, France.
- CHU de Brest, Service de néphrologie et transplantations rénales, Brest, France.
- Univ Brest, Univ Angers, Infections Respiratoires Fongiques, Brest, France.
- Univ Angers, Univ Brest, Infections Respiratoires Fongiques, SFR ICAT, Angers, France.
- CHU de Brest, Laboratoire de Parasitologie-Mycologie, Brest, France; Univ Brest, Univ Angers, Infections Respiratoires Fongiques, Brest, France. Electronic address: solene.legal@univ-brest.fr.
Förderung
- Chiesi Pharmaceuticals
Zitieren
APA
Hoffmann, C. V., Le Meur, Y., Moal, M. C., Grall-Jézéquel, A., Le Nan, N., Papon, N., Nevez, G., Le Gal, S., & Pneumocystis IMPDH Study Group (2025). Association between mycophenolic acid treatment and infection with specific strains of Pneumocystis jirovecii in solid organ transplant recipients in France and Switzerland: a multicentre, retrospective, cross-sectional study. The Lancet Microbe. https://doi.org/10.1016/j.lanmic.2025.101146
Vancouver
Hoffmann CV, Le Meur Y, Moal MC, Grall-Jézéquel A, Le Nan N, Papon N, et al. Association between mycophenolic acid treatment and infection with specific strains of Pneumocystis jirovecii in solid organ transplant recipients in France and Switzerland: a multicentre, retrospective, cross-sectional study. The Lancet Microbe. 2025. doi:10.1016/j.lanmic.2025.101146
BibTeX
@article{Hoffmann2025,
author = {Hoffmann, Claire V and Le Meur, Yannick and Moal, Marie-Christine and Grall-Jézéquel, Anne and Le Nan, Nathan and Papon, Nicolas and Nevez, Gilles and Le Gal, Solène and Pneumocystis IMPDH Study Group, Pneumocystis IMPDH Study Group},
title = {Association between mycophenolic acid treatment and infection with specific strains of Pneumocystis jirovecii in solid organ transplant recipients in France and Switzerland: a multicentre, retrospective, cross-sectional study},
journal = {The Lancet Microbe},
year = {2025},
doi = {10.1016/j.lanmic.2025.101146}
}
EUVIMED